|
Oncology Competitive Intelligence Leaders
Executive Summary: ONCrg analysts Kristen Cordova and Amber Mineo walk through the highest-impact lung cancer presentations from WCLC 2026 and preview what to watch at ESMO 2026 across small cell and non-small cell lung cancer, covering the context of each readout, how the treatment landscape is expected to shift, and the key questions the analyst team will be chasing.
Join our team as we break down the major readouts shaping thoracic oncology, including: 1L EGFR ex20ins+ NSCLC: First Phase III data for zipalertinib TKI-Naive ROS1+ NSCLC: Potentially registrational data for zidesamtinib 1L HER2m+ NSCLC: First Phase III data readout for T-DXd Relapsed SCLC: First CN Phase III data on two B7-H3 ADCs (tambotatug pelitecan […]
Our team will be tracking the latest breakthroughs and clinical updates shaping thoracic oncology. Planning your conference coverage or need strategic intelligence from WCLC? Start with our ONCrg planner. ONCrg is anticipating: • Data on novel therapies in NSCLC patient subsets with high unmet need: • First Phase III data for zipalertinib in 1L EGFR […]
Medical Conference Coverage EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026 ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 ICML: June 15-19, 2027 Antibody-Drug Conjugates (ADCs) […]
Excerpt from Custom Post Type Indication: Cell Therapies
Excerpt from Custom Post Type Indication: SCLC
Therapy Area Director, Oncology